ATE364392T1 - Zusammensetzung aus liganden/lytischen petiden und ihre verwendung - Google Patents
Zusammensetzung aus liganden/lytischen petiden und ihre verwendungInfo
- Publication number
- ATE364392T1 ATE364392T1 AT98913218T AT98913218T ATE364392T1 AT E364392 T1 ATE364392 T1 AT E364392T1 AT 98913218 T AT98913218 T AT 98913218T AT 98913218 T AT98913218 T AT 98913218T AT E364392 T1 ATE364392 T1 AT E364392T1
- Authority
- AT
- Austria
- Prior art keywords
- ligand
- cells
- lytic peptide
- peptide
- lytic
- Prior art date
Links
- 230000002101 lytic effect Effects 0.000 title abstract 9
- 239000003446 ligand Substances 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 9
- 210000004027 cell Anatomy 0.000 abstract 7
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 3
- 230000009089 cytolysis Effects 0.000 abstract 3
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 3
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 230000007774 longterm Effects 0.000 abstract 2
- 210000004698 lymphocyte Anatomy 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101710112752 Cytotoxin Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000002619 cytotoxin Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 239000000813 peptide hormone Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Insects & Arthropods (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4100997P | 1997-03-27 | 1997-03-27 | |
| US86915397A | 1997-06-04 | 1997-06-04 | |
| US5745697P | 1997-09-03 | 1997-09-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE364392T1 true ATE364392T1 (de) | 2007-07-15 |
Family
ID=27365827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98913218T ATE364392T1 (de) | 1997-03-27 | 1998-03-27 | Zusammensetzung aus liganden/lytischen petiden und ihre verwendung |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP0975354B1 (de) |
| JP (1) | JP2000514836A (de) |
| AT (1) | ATE364392T1 (de) |
| AU (1) | AU6587998A (de) |
| CA (1) | CA2283630C (de) |
| DE (1) | DE69837915T2 (de) |
| ES (1) | ES2289775T3 (de) |
| WO (2) | WO1998042364A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10292896D2 (de) * | 2001-07-05 | 2004-07-01 | Univ Goettingen Georg August | Gentherapeutisches Verfahren zur Behandlung von GnRH-Rezeptor-positiven Karzinomen durch GnRH induzierte tumorzellspezifische Aktivierung eines therapeutischen Gens, zugehörige Nukleinsäurekonstrukte und Vektoren |
| EP1273309A1 (de) * | 2001-07-05 | 2003-01-08 | Georg-August Universität Göttingen | Gentherapeutisches Verfahren zur Behandlung von GnRH-Rezeptor-positiven Karzinomen durch GnRH induzierte tumorzellspezifische Aktivierung eines therapeutischen Gens, zugehörige Nukleinsäurekonstrukte und Vektoren |
| JP5616233B2 (ja) | 2008-01-24 | 2014-10-29 | エスペランス ファーマシューティカルズＥｓｐｅｒａｎｃｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ | 溶解ドメイン融合コンストラクト及びその生成及び使用方法 |
| AU2010212513B2 (en) | 2009-10-02 | 2016-08-25 | Monash University | Ectopic pregnancy treatment |
| US9586996B2 (en) * | 2010-04-30 | 2017-03-07 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| US20120270770A1 (en) * | 2010-08-03 | 2012-10-25 | Jesse Michael Jaynes | Anti-angiogenic peptides and their uses |
| AU2013337926B2 (en) | 2012-10-30 | 2017-12-21 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
| EP3206704B1 (de) * | 2014-10-14 | 2022-04-20 | Riptide Bioscience, Inc. | Peptide mit entzündungshemmenden eigenschaften |
| US10413584B1 (en) | 2018-08-29 | 2019-09-17 | Riptide Bioscience, Inc. | Peptides having immunomodulatory properties |
| US10548944B1 (en) | 2018-10-19 | 2020-02-04 | Riptide Bioscience, Inc. | Antimicrobial peptides and methods of using the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1203672B (it) * | 1982-05-12 | 1989-02-15 | Harvard College | Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina |
| US5135736A (en) * | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| WO1990009799A1 (en) * | 1989-02-23 | 1990-09-07 | Colorado State University Research Foundation | GnRH ANALOGS FOR DESTROYING GONADOTROPHS |
| WO1990012866A1 (en) * | 1989-04-10 | 1990-11-01 | Louisiana State University And Agricultural And Mechanical College | Lytic peptides, use for growth, infection and cancer |
| PH30997A (en) * | 1990-03-12 | 1997-12-23 | Ciba Geigy | Antipathologenically effective compositions comprising lytic peptides and hydrolytic enzymes. |
| WO1993015751A1 (en) * | 1992-02-14 | 1993-08-19 | Merck & Co., Inc. | CHIMERIC TOXINS BINDING TO THE GnRH RECEPTOR |
| CA2160909A1 (en) * | 1993-04-28 | 1994-11-10 | Hagan Bayley | Cell-targeted lytic pore-forming agents |
| IL114697A0 (en) * | 1994-07-22 | 1995-11-27 | Demeter Biotech Ltd | Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use |
| US5589457A (en) * | 1995-07-03 | 1996-12-31 | Ausa International, Inc. | Process for the synchronization of ovulation |
-
1998
- 1998-03-26 AU AU65879/98A patent/AU6587998A/en not_active Abandoned
- 1998-03-27 CA CA2283630A patent/CA2283630C/en not_active Expired - Lifetime
- 1998-03-27 JP JP10546026A patent/JP2000514836A/ja active Pending
- 1998-03-27 AT AT98913218T patent/ATE364392T1/de not_active IP Right Cessation
- 1998-03-27 WO PCT/US1998/006013 patent/WO1998042364A1/en not_active Application Discontinuation
- 1998-03-27 DE DE69837915T patent/DE69837915T2/de not_active Expired - Lifetime
- 1998-03-27 WO PCT/US1998/006114 patent/WO1998042365A1/en active IP Right Grant
- 1998-03-27 ES ES98913218T patent/ES2289775T3/es not_active Expired - Lifetime
- 1998-03-27 EP EP98913218A patent/EP0975354B1/de not_active Expired - Lifetime
- 1998-03-27 EP EP98912077A patent/EP0988048A4/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0988048A4 (de) | 2003-05-28 |
| JP2000514836A (ja) | 2000-11-07 |
| WO1998042365A1 (en) | 1998-10-01 |
| DE69837915T2 (de) | 2008-02-21 |
| EP0975354B1 (de) | 2007-06-13 |
| ES2289775T3 (es) | 2008-02-01 |
| DE69837915D1 (de) | 2007-07-26 |
| EP0975354A1 (de) | 2000-02-02 |
| CA2283630A1 (en) | 1998-10-01 |
| WO1998042364A1 (en) | 1998-10-01 |
| CA2283630C (en) | 2011-08-30 |
| AU6587998A (en) | 1998-10-20 |
| EP0988048A1 (de) | 2000-03-29 |
| EP0975354A4 (de) | 2003-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Enhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted delivery | |
| BE2014C040I2 (de) | ||
| Chang et al. | Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist | |
| MXPA05008128A (es) | Peptidos derivados de survivina y uso de los mismos. | |
| AU2005270336A1 (en) | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent | |
| NZ337955A (en) | Modified TNF-alpha and their use as vaccines | |
| MXPA05005330A (es) | Composiciones y formulaciones de gastrina, y metodos de uso y preparacion. | |
| ATE364392T1 (de) | Zusammensetzung aus liganden/lytischen petiden und ihre verwendung | |
| AU1385699A (en) | Novel conjugates of rgd-containing peptides and endogenous carriers | |
| Cash et al. | Structure—activity relations of the fibrinolytic response to vasopressins in man | |
| Rao et al. | 99mTc-peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumours | |
| BG106008A (en) | Novel lhrh antagonists with improved solubility characteristics | |
| NZ333203A (en) | Tumour antigen proteins, genes thereof, and tumour antigen peptides | |
| Zhang et al. | Selective Cyclized α-Melanocyte-Stimulating Hormone Derivative with Multiple N-Methylations for Melanoma Imaging with Positron Emission Tomography | |
| AR016427A1 (es) | CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE. | |
| HK1076601A1 (en) | Polypeptide, the conjugate thereof with doxorubicine and a pharmaceutical composition based thereon | |
| EP1878438A3 (de) | Ligand-/lytische Peptidzusammensetzungen und Verwendungsverfahren | |
| Bapst et al. | Dimeric DOTA-α-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity | |
| DE69910809D1 (de) | Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern | |
| JP2004529886A (ja) | 血液脳関門を通して鎮痛分子をベクター化することが可能なベクターに結合した前記鎮痛分子からなる化合物、及びそれらを含む医薬組成物 | |
| CA2351944A1 (en) | Hydrophilic somatostatin analogs | |
| Wong et al. | Exploiting the receptor-binding domains of R-spondin 1 to target leucine-rich repeat-containin G-coupled protein receptor 5-expressing stem cells in ovarian cancer | |
| US20030073621A1 (en) | Beta-lipotropin and uses thereof | |
| SE9302414L (sv) | Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid | |
| Gozes | In memory of victor mutt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |